Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans.

May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, Audia JE, Boggs LN, Borders AR, Brier RA, Calligaro DO, Day TA, Ereshefsky L, Erickson JA, Gevorkyan H, Gonzales CR, James DE, Jhee SS, Komjathy SF, Li L, Lindstrom TD, Mathes BM, Martényi F, Sheehan SM, Stout SL, Timm DE, Vaught GM, Watson BM, Winneroski LL, Yang Z, Mergott DJ.

J Neurosci. 2015 Jan 21;35(3):1199-210. doi: 10.1523/JNEUROSCI.4129-14.2015.

2.

Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384.

Katz DA, Liu W, Locke C, Jacobson P, Barnes DM, Basu R, An G, Rieser MJ, Daszkowski D, Groves F, Heneghan G, Shah A, Gevorkyan H, Jhee SS, Ereshefsky L, Marek GJ.

Transl Psychiatry. 2013 Aug 27;3:e295. doi: 10.1038/tp.2013.67.

3.

Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects.

Liang E, Garzone P, Cedarbaum JM, Koller M, Tran T, Xu V, Ross B, Jhee SS, Ereshefsky L, Pastrak A, Abushakra S.

Clin Pharmacol Drug Dev. 2013 Apr;2(2):186-94. doi: 10.1002/cpdd.14. Epub 2013 Mar 16.

PMID:
27121673
4.

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.

May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, Cocke PJ, Greg Hall D, Friedrich S, Citron M, Audia JE.

J Neurosci. 2011 Nov 16;31(46):16507-16. doi: 10.1523/JNEUROSCI.3647-11.2011.

5.

Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels.

Li J, Llano DA, Ellis T, LeBlond D, Bhathena A, Jhee SS, Ereshefsky L, Lenz R, Waring JF.

Alzheimers Dement. 2012 Jul;8(4):295-303. doi: 10.1016/j.jalz.2011.05.900. Epub 2011 Nov 2.

PMID:
22047633
6.

Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers.

Jhee SS, Yen M, Ereshefsky L, Leibowitz M, Schulte M, Kaeser B, Boak L, Patel A, Hoffmann G, Prinssen EP, Rayner CR.

Antimicrob Agents Chemother. 2008 Oct;52(10):3687-93. doi: 10.1128/AAC.00327-08. Epub 2008 Aug 1.

7.

Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.

Lefèvre G, Sedek G, Jhee SS, Leibowitz MT, Huang HL, Enz A, Maton S, Ereshefsky L, Pommier F, Schmidli H, Appel-Dingemanse S.

Clin Pharmacol Ther. 2008 Jan;83(1):106-14. Epub 2007 May 23.

PMID:
17522596
8.

Identifying pharmacodynamic protein markers of centrally active drugs in humans: a pilot study in a novel clinical model.

Patil ST, Higgs RE, Brandt JE, Knierman MD, Gelfanova V, Butler JP, Downing AM, Dorocke J, Dean RA, Potter WZ, Michelson D, Pan AX, Jhee SS, Hale JE.

J Proteome Res. 2007 Mar;6(3):955-66. Epub 2007 Jan 23.

PMID:
17243662
9.

Multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjects.

Jhee SS, Chappell AS, Zarotsky V, Moran SV, Rosenthal M, Kim E, Chalon S, Toublanc N, Brandt J, Coutant DE, Ereshefsky L.

J Clin Pharmacol. 2006 Apr;46(4):424-32.

PMID:
16554450
10.

Pharmacokinetics of rizatriptan tablets during and between migraine attacks.

Cutler NR, Jhee SS, Majumdar AK, McLaughlin D, Brucker MJ, Carides AD, Kramer MS, Matzura-Wolfe D, Reines SA, Goldberg MR.

Headache. 1999 Apr;39(4):264-9.

PMID:
15613223
11.

Similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy caucasian and Japanese american subjects.

Jhee SS, Lyness WH, Rojas PB, Leibowitz MT, Zarotsky V, Jacobsen LV.

J Clin Pharmacol. 2004 Mar;44(3):258-64.

PMID:
14973299
12.

Delayed onset of oculogyric crisis and torticollis with intramuscular haloperidol.

Jhee SS, Zarotsky V, Mohaupt SM, Yones CL, Sims SJ.

Ann Pharmacother. 2003 Oct;37(10):1434-7.

PMID:
14519055
13.

First clinical evaluation of ganstigmine in patients with probable Alzheimer's disease.

Jhee SS, Fabbri L, Piccinno A, Monici P, Moran S, Zarotsky V, Tan EY, Frackiewicz EJ, Shiovitz T.

Clin Neuropharmacol. 2003 May-Jun;26(3):164-9.

PMID:
12782920
14.

Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine.

Jhee SS, Shiovitz T, Hartman RD, Messina J, Anand R, Sramek J, Cutler NR.

Clin Neuropharmacol. 2002 Mar-Apr;25(2):122-3. No abstract available.

PMID:
11981242
15.

Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type.

Hossain M, Jhee SS, Shiovitz T, McDonald C, Sedek G, Pommier F, Cutler NR.

Clin Pharmacokinet. 2002;41(3):225-34.

PMID:
11929322
16.

Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa.

Frackiewicz EJ, Jhee SS, Shiovitz TM, Webster J, Topham C, Dockens RC, Whigan D, Salazar DE, Cutler NR.

Ann Pharmacother. 2002 Feb;36(2):225-30.

PMID:
11847938
17.

Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease.

Gobburu JV, Tammara V, Lesko L, Jhee SS, Sramek JJ, Cutler NR, Yuan R.

J Clin Pharmacol. 2001 Oct;41(10):1082-90.

PMID:
11583476
18.

Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review.

Jhee SS, Shiovitz T, Crawford AW, Cutler NR.

Clin Pharmacokinet. 2001;40(3):189-205. Review.

PMID:
11327198
19.

A bridging study of fananserin in schizophrenic patients.

Sramek JJ, Kirkesseli S, Paccaly-Moulin A, Davidson J, Jhee SS, Hourani J, Sémiond D, Cutler NR.

Psychopharmacol Bull. 1998;34(4):811-8.

PMID:
10513457
20.
21.

NXX-066 in patients with Alzheimer's disease: a bridging study.

Sramek JJ, Hourani J, Jhee SS, Cutler NR.

Life Sci. 1999;64(14):1215-21.

PMID:
10210264
22.

Pharmacokinetics and pharmacodynamics of avitriptan in patients with migraine after oral dosing.

Cutler NR, Salazar DE, Jhee SS, Fulmor IE, Ford N, Smith RA, Sramek JJ.

Headache. 1998 Jun;38(6):446-52.

PMID:
9664749
23.

Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study.

Cutler NR, Jhee SS, Cyrus P, Bieber F, TanPiengco P, Sramek JJ, Gulanski B.

Life Sci. 1998;62(16):1433-41.

PMID:
9585171
24.

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.

Cutler NR, Polinsky RJ, Sramek JJ, Enz A, Jhee SS, Mancione L, Hourani J, Zolnouni P.

Acta Neurol Scand. 1998 Apr;97(4):244-50.

PMID:
9576639
25.

Initial safety, tolerability pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia.

Sramek JJ, Eldon MA, Posvar E, Feng MR, Jhee SS, Hourani J, Sedman AJ, Cutler NR.

Psychopharmacol Bull. 1998;34(1):93-9.

PMID:
9564205
26.

Monitoring of acute migraine attacks: placebo response and safety data.

Jhee SS, Salazar DE, Ford NF, Fulmor IE, Sramek JJ, Cutler NR.

Headache. 1998 Jan;38(1):35-8.

PMID:
9505001
27.

A bridging study of LU 25-109 in patients with probable Alzheimer's disease.

Sramek JJ, Forrest M, Mengel H, Jhee SS, Hourani J, Cutler NR.

Life Sci. 1998;62(3):195-202.

PMID:
9488097
28.

Two rapid-dose titrations of sertindole in patients with schizophrenia.

Sramek JJ, Mack RJ, Awni W, Hourani J, Jhee SS, Barto S, Cutler NR.

J Clin Psychopharmacol. 1997 Oct;17(5):419-22.

PMID:
9315993
29.

Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin.

Cutler NR, Vincent J, Jhee SS, Teng R, Wardle T, Lucas G, Dogolo LC, Sramek JJ.

Antimicrob Agents Chemother. 1997 Jun;41(6):1298-300.

30.

Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: a bridging study.

Sramek JJ, Fresquet A, Marion-Landais G, Hourani J, Jhee SS, Martinez L, Jensen CM, Bolles K, Carrington AT, Cutler NR.

J Clin Psychopharmacol. 1996 Dec;16(6):454-8.

PMID:
8959472
31.

Evaluation of cycloserine in the treatment of Alzheimer's disease.

Fakouhi TD, Jhee SS, Sramek JJ, Benes C, Schwartz P, Hantsburger G, Herting R, Swabb EA, Cutler NR.

J Geriatr Psychiatry Neurol. 1995 Oct;8(4):226-30.

PMID:
8561836
32.

Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections.

Jhee SS, Kern JW, Burm JP, Yellin AE, Gill MA.

Pharmacotherapy. 1995 Jul-Aug;15(4):472-8.

PMID:
7479200
33.

Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris.

Cutler NR, Anders RJ, Jhee SS, Sramek JJ, Awan NA, Bultas J, Lahiri A, Woroszylska M.

Am J Cardiol. 1995 Jun 1;75(16):1102-6.

PMID:
7762493
34.

Orthostasis in Alzheimer disease: a retrospective analysis.

Jhee SS, Sramek JJ, Wardle TS, Cutler NR.

Alzheimer Dis Assoc Disord. 1995 Winter;9(4):243-6.

PMID:
8749615
35.

Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections.

Jhee SS, Gill MA, Yellin AE, Berne TV, Heseltine PN, Appleman MD.

Clin Ther. 1995 Jan-Feb;17(1):126-35.

PMID:
7758055
36.

Stability of paclitaxel and fluconazole during simulated Y-site administration.

Burm JP, Choi JS, Jhee SS, Chin A, Ulrich RW, Gill MA.

Am J Hosp Pharm. 1994 Nov 1;51(21):2704-6. No abstract available.

PMID:
7856586
37.
38.
39.

Stability of paclitaxel with ondansetron hydrochloride or ranitidine hydrochloride during simulated Y-site administration.

Burm JP, Jhee SS, Chin A, Moon YS, Jeong E, Nii L, Fox JL, Gill MA.

Am J Hosp Pharm. 1994 May 1;51(9):1201-4.

PMID:
7913797
40.

Stability of ondansetron hydrochloride stored in a disposable, elastomeric infusion device at 4 degrees C.

Jhee SS, Jeong EW, Chin A, Inagaki K, Fox JL, Gill MA.

Am J Hosp Pharm. 1993 Sep;50(9):1918-20. No abstract available.

PMID:
8135242

Supplemental Content

Support Center